Sandbox Rim: Difference between revisions

Jump to navigation Jump to search
Line 4: Line 4:
<span style="font-size:85%">Boxes in the red color signify that an urgent management is needed.</span>
<span style="font-size:85%">Boxes in the red color signify that an urgent management is needed.</span>
{{Family tree/start}}
{{Family tree/start}}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF;  | | | | A00 | | A00=<div style="float: left; text-align: left; width: 25em; padding:1em;"> '''Identify cardinal findings of unstable angina/ NSTEMI :''' <br>
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF;  | | | | A00 | | A00=<div style="float: left; text-align: left; width: 20em; padding:1em;"> '''Identify cardinal findings of unstable angina/ NSTEMI :''' <br>
❑ '''[[Chest pain|<span style="color:white;"> Chest pain</span>]] or [[chest discomfort|<span style="color:white;">chest discomfort</span>]]''' <br>
❑ '''[[Chest pain|<span style="color:white;"> Chest pain</span>]] or [[chest discomfort|<span style="color:white;">chest discomfort</span>]]''' <br>
:❑ Sudden onset
:❑ Sudden onset
Line 22: Line 22:
❑ '''Increase in >99th percentile of upper limit of normal of [[troponin|<span style="color:white;">troponin</span>]] and / or [[CKMB|<span style="color:white;">CK MB </span>]]''', which is consistent with [[NSTEMI|<span style="color:white;">NSTEMI</span>]]</div>}}
❑ '''Increase in >99th percentile of upper limit of normal of [[troponin|<span style="color:white;">troponin</span>]] and / or [[CKMB|<span style="color:white;">CK MB </span>]]''', which is consistent with [[NSTEMI|<span style="color:white;">NSTEMI</span>]]</div>}}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF;  | | | | |!| | | }}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF;  | | | | |!| | | }}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF;  | | | | G02 | G02= <div style="float: left; text-align: left; width: 25em; padding:1em;"> '''Rule out life threatening alternative diagnoses:'''<br>
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF;  | | | | G02 | G02= <div style="float: left; text-align: left; width: 20em; padding:1em;"> '''Rule out life threatening alternative diagnoses:'''<br>
❑ [[Aortic dissection|<span style="color:white;">Aortic dissection</span>]] <br> (suggestive findings: [[back pain|<span style="color:white;">back pain</span>]], [[interscapular pain|<span style="color:white;">interscapular pain</span>]], [[aortic regurgitation|<span style="color:white;">aortic regurgitation</span>]], [[pulsus paradoxus|<span style="color:white;">pulsus paradoxus</span>]], [[blood pressure|<span style="color:white;">blood pressure</span>]] discrepancy between the arms) <br>
❑ [[Aortic dissection|<span style="color:white;">Aortic dissection</span>]] <br> (suggestive findings: [[back pain|<span style="color:white;">back pain</span>]], [[interscapular pain|<span style="color:white;">interscapular pain</span>]], [[aortic regurgitation|<span style="color:white;">aortic regurgitation</span>]], [[pulsus paradoxus|<span style="color:white;">pulsus paradoxus</span>]], [[blood pressure|<span style="color:white;">blood pressure</span>]] discrepancy between the arms) <br>
❑ [[Pulmonary embolism|<span style="color:white;">Pulmonary embolism</span>]] <br> (suggestive findings: acute onset of [[dyspnea|<span style="color:white;">dyspnea</span>]], [[tachypnea|<span style="color:white;">tachypnea</span>]], [[hemoptysis|<span style="color:white;">hemoptysis</span>]], previous [[DVT|<span style="color:white;">DVT</span>]]) <br>
❑ [[Pulmonary embolism|<span style="color:white;">Pulmonary embolism</span>]] <br> (suggestive findings: acute onset of [[dyspnea|<span style="color:white;">dyspnea</span>]], [[tachypnea|<span style="color:white;">tachypnea</span>]], [[hemoptysis|<span style="color:white;">hemoptysis</span>]], previous [[DVT|<span style="color:white;">DVT</span>]]) <br>
Line 29: Line 29:
❑ [[Esophageal rupture|<span style="color:white;">Esophageal rupture</span>]] <br> (suggestive findings: [[vomiting|<span style="color:white;">vomiting</span>]], [[subcutaneous emphysema|<span style="color:white;">subcutaneous emphysema</span>]])</div>}}
❑ [[Esophageal rupture|<span style="color:white;">Esophageal rupture</span>]] <br> (suggestive findings: [[vomiting|<span style="color:white;">vomiting</span>]], [[subcutaneous emphysema|<span style="color:white;">subcutaneous emphysema</span>]])</div>}}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF;  | | | | |!| | | }}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF;  | | | | |!| | | }}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF;  | | | | A01 | | | | | A01= <div style="float: left; text-align: left; width: 25em; padding:1em;">'''Begin initial treatment:'''<br>  ❑ Administer [[aspirin|<span style="color:white;">aspirin</span>]] (I-A)
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF;  | | | | A01 | | | | | A01= <div style="float: left; text-align: left; width: 20em; padding:1em;">'''Begin initial treatment:'''<br>  ❑ Administer [[aspirin|<span style="color:white;">aspirin</span>]] (I-A)
:❑ 162 to 325 mg of non enteric [[aspirin|<span style="color:white;">aspirin</span>]],orally, crushed or chewed, THEN
:❑ 162 to 325 mg of non enteric [[aspirin|<span style="color:white;">aspirin</span>]],orally, crushed or chewed, THEN
:❑ 75 to 325 mg/day
:❑ 75 to 325 mg/day
Line 48: Line 48:
</div>}}
</div>}}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF;  | | | | |!| | | }}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF;  | | | | |!| | | }}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF;  | | | | G01 | G01= <div style="float: left; text-align: left; width: 25em; padding:1em;"> '''Does the patient have any of the following indications that require immediate angiography and revascularization ?'''
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF;  | | | | G01 | G01= <div style="float: left; text-align: left; width: 20em; padding:1em;"> '''Does the patient have any of the following indications that require immediate angiography and revascularization ?'''
❑ Hemodynamic instability or [[cardiogenic shock|<span style="color:white;">cardiogenic shock </span>]] <br>
❑ Hemodynamic instability or [[cardiogenic shock|<span style="color:white;">cardiogenic shock </span>]] <br>
❑ Severe left ventricular dysfunction or [[heart failure|<span style="color:white;">heart failure </span>]] <br>
❑ Severe left ventricular dysfunction or [[heart failure|<span style="color:white;">heart failure </span>]] <br>
Line 56: Line 56:
❑ Prior [[PCI|<span style="color:white;">PCI </span>]] within past 6 months or [[CABG|<span style="color:white;">CABG </span>]] <br> </div> }}
❑ Prior [[PCI|<span style="color:white;">PCI </span>]] within past 6 months or [[CABG|<span style="color:white;">CABG </span>]] <br> </div> }}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |,|-|-|^|-|-|.| | }}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |,|-|-|^|-|-|.| | }}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | C01 | | | | C02 | | | C01=<div style="float: left; text-align: center; width: 25em; padding:1em;">'''YES''' </div>| C02= <div style="float: left; text-align: center; width: 25em; padding:1em;">'''NO''' </div> }}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | C01 | | | | C02 | | | C01=<div style="float: left; text-align: center; width: 20em; padding:1em;">'''YES''' </div>| C02= <div style="float: left; text-align: center; width: 20em; padding:1em;">'''NO''' </div> }}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | | | |!| | | | }}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | | | |!| | | | }}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | | | C03 | | | C03=<div style="float: left; text-align: left; width: 25em; padding:1em;">Does the patient have negative ECG findings AND negative biomarkers?</div>}}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | | | C03 | | | C03=<div style="float: left; text-align: left; width: 20em; padding:1em;">Does the patient have negative ECG findings AND negative biomarkers?</div>}}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | |,|-|^|-|.| | }}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | |,|-|^|-|.| | }}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | C04 | | C05 |  C04= Yes | C05= No}}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | C04 | | C05 |  C04= Yes | C05= No}}
Line 66: Line 66:
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| C07 | | C08 |!| C07= ECG and biomarkers are both negative | C08= At least one (ECG or biomarkers) is positive}}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| C07 | | C08 |!| C07= ECG and biomarkers are both negative | C08= At least one (ECG or biomarkers) is positive}}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| |!| | | |!| |!| }}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| |!| | | |!| |!| }}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!|C09  | | | C10 | | | C09= <div style="float: left; text-align: left; width: 25em; padding:1em;">[[Chest pain resident survival guide#Complete Diagnostic Approach|Proceed to complete diagnostic approach of chest pain to rule out differential diagnoses]]</div>| C10=<div style="float: left; text-align: left; width: 25em; padding:1em;">'''Calculate the risk of future adverse clinical outcomes:'''<br>
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!|C09  | | | C10 | | | C09= <div style="float: left; text-align: left; width: 20em; padding:1em;">[[Chest pain resident survival guide#Complete Diagnostic Approach|Proceed to complete diagnostic approach of chest pain to rule out differential diagnoses]]</div>| C10=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Calculate the risk of future adverse clinical outcomes:'''<br>
❑ [[TIMI risk score|<span style="color:white;">Thrombolysis in Myocardial Infarction (TIMI) risk score</span>]], OR
❑ [[TIMI risk score|<span style="color:white;">Thrombolysis in Myocardial Infarction (TIMI) risk score</span>]], OR
❑ [[GRACE score|<span style="color:white;">GRACE score</span>]] </div>}}
❑ [[GRACE score|<span style="color:white;">GRACE score</span>]] </div>}}
Line 73: Line 73:
| D02= <div style="float: left; text-align: center; width: 20em; padding:1em;"> '''Intermediate or high risk''' <br> '''Initial invasive strategy''' </div>| D03= <div style="float: left; text-align: center; width: 20em; padding:1em;"> '''Low risk''' <br> '''Initial conservative strategy''' </div>}}
| D02= <div style="float: left; text-align: center; width: 20em; padding:1em;"> '''Intermediate or high risk''' <br> '''Initial invasive strategy''' </div>| D03= <div style="float: left; text-align: center; width: 20em; padding:1em;"> '''Low risk''' <br> '''Initial conservative strategy''' </div>}}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | |!| | | |!| | }}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | |!| | | |!| | }}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | E01 | | E02 | | E03 |E01=<div style="float: left; text-align: left; width: 25em; padding:1em;">
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | E01 | | E02 | | E03 |E01=<div style="float: left; text-align: left; width: 20em; padding:1em;">
'''Administer ONE of the following antiplatelet agents (before or at the time of PCI):''' <br>
'''Administer ONE of the following antiplatelet agents (before or at the time of PCI):''' <br>
❑ Loading dose of [[P2Y12|<span style="color:white;">P2Y12</span>]] receptor inhibitors <br>
❑ Loading dose of [[P2Y12|<span style="color:white;">P2Y12</span>]] receptor inhibitors <br>
Line 140: Line 140:
:❑ Maintenance dose for up to 12 months (90 mg twice daily)</div>}}
:❑ Maintenance dose for up to 12 months (90 mg twice daily)</div>}}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | |!| | | |!| | }}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | |!| | | |!| | }}
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | F01 | | F02 | | F03 | |F01=<div style="float: left; text-align: left; width: 25em; padding:1em;"> '''Consider urgent [[CABG|<span style="color:white;">CABG</span>]] if the coronary anatomy is not amenable to PCI and one of the following:'''<ref name="www.ncbi.nlm.nih.gov">{{Cite web  | last =  | first =  | title = ACC/AHA 2004 guideline update for coronary arter... [Circulation. 2004] - PubMed - NCBI | url = http://www.ncbi.nlm.nih.gov/pubmed?term=15466654 | publisher =  | date =  | accessdate = }}</ref> <br> ❑ Patients with left main or left main equivalent disease <br> ❑ Patients with three or two vessel disease involving the left anterior descending artery with left ventricular dysfunction <br> ❑ Diabetic patients </div>|F02=<div style="float: left; text-align: left; width: 25em; padding:1em;"> ❑ Perform an [[angiography|<span style="color:white;">angiography</span>]] </div>|F03='''Does the patient experience any of the following?''' <br>
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | F01 | | F02 | | F03 | |F01=<div style="float: left; text-align: left; width: 20em; padding:1em;"> '''Consider urgent [[CABG|<span style="color:white;">CABG</span>]] if the coronary anatomy is not amenable to PCI and one of the following:'''<ref name="www.ncbi.nlm.nih.gov">{{Cite web  | last =  | first =  | title = ACC/AHA 2004 guideline update for coronary arter... [Circulation. 2004] - PubMed - NCBI | url = http://www.ncbi.nlm.nih.gov/pubmed?term=15466654 | publisher =  | date =  | accessdate = }}</ref> <br> ❑ Patients with left main or left main equivalent disease <br> ❑ Patients with three or two vessel disease involving the left anterior descending artery with left ventricular dysfunction <br> ❑ Diabetic patients </div>|F02=<div style="float: left; text-align: left; width: 20em; padding:1em;"> ❑ Perform an [[angiography|<span style="color:white;">angiography</span>]] </div>|F03='''Does the patient experience any of the following?''' <br>
❑ Recurrence of symptoms<br>
❑ Recurrence of symptoms<br>
❑ [[Heart failure|<span style="color:white;">Heart failure</span>]]<br>
❑ [[Heart failure|<span style="color:white;">Heart failure</span>]]<br>

Revision as of 02:42, 7 April 2015

FIRE: Focused Initial Rapid Evaluation

A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention based on the 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction.[1]

Boxes in the red color signify that an urgent management is needed.

 
 
 
Identify cardinal findings of unstable angina/ NSTEMI :

Chest pain or chest discomfort

❑ Sudden onset
❑ Sensation of heaviness, tightness, pressure, or squeezing
❑ Duration> 20 minutes (but usually less than half an hour)
❑ Radiation to the left arm, jaw, neck, right arm, back or epigastrium
❑ No relief with medications
❑ No relief with rest
❑ Worse with time
❑ Worse with exertion
❑ Associated symptoms of palpitations, nausea, vomiting, sweating, dyspnea, and lightheadedness

Characteristic ECG changes consistent with unstable angina/ NSTEMI

❑ No changes
❑ Non specific ST / T wave changes
❑ Flipped or inverted T waves
❑ ST depression (carries the poorest prognosis)
Increase in >99th percentile of upper limit of normal of troponin and / or CK MB , which is consistent with NSTEMI
 
 
 
 
 
 
 
 
 
 
 
 
 
Rule out life threatening alternative diagnoses:

Aortic dissection
(suggestive findings: back pain, interscapular pain, aortic regurgitation, pulsus paradoxus, blood pressure discrepancy between the arms)
Pulmonary embolism
(suggestive findings: acute onset of dyspnea, tachypnea, hemoptysis, previous DVT)
Cardiac tamponade
(suggestive findings: hypotension, jugular venous distention, muffled heart sounds, pulsus paradoxus)
Tension pneumothorax
(suggestive findings: sudden dyspnea, tachycardia, chest trauma, unilateral absence of breath sound)

Esophageal rupture
(suggestive findings: vomiting, subcutaneous emphysema)
 
 
 
 
 
 
 
 
 
 
 
 
Begin initial treatment:
❑ Administer aspirin (I-A)
❑ 162 to 325 mg of non enteric aspirin,orally, crushed or chewed, THEN
❑ 75 to 325 mg/day
Among patients with either GI intolerance or hypersensitivity against it, administer a loading dose followed by maintenance dose of either clopidogrel (I-B), or prasugrel in PCI patients (I-C), or ticagrelor (I-C)

❑ Administer 2-4 L/min oxygen via nasal cannula when saturation <90%

❑ Caution in COPD patients: maintain an oxygen saturation between 88% and 92%

❑ Administer beta-blockers (unless contraindicated) and titrate to the heart rate and blood pressure
Contraindicated in heart failure , prolonged or high degree AV block , reactive airway disease , high risk of cardiogenic shock and low cardiac output state

Metoprolol IV, 5 mg every 5 min, up to 3 doses, then 25 to 50 mg orally every 6 hours
Carvedilol IV, 25 mg, two times a day

❑ Administer sublingual nitroglycerin 0.4 mg every 5 minutes for a total of 3 doses
Contraindicated in suspected right ventricular MI , recent use of phosphodiesterase inhibitors , decreased blood pressure 30 mmHg below baseline
❑ Administer IV morphine if persistent symptoms or pulmonary edema

❑ Initial dose 4-8 mg
❑ 2-8 mg every 5 to 15 minutes, as needed

❑ Administer 80 mg atorvastatin
❑ Monitor with a 12-lead ECG all the time

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Does the patient have any of the following indications that require immediate angiography and revascularization ?

❑ Hemodynamic instability or cardiogenic shock
❑ Severe left ventricular dysfunction or heart failure
❑ Recurrent or persistent rest angina despite intensive medical therapy
❑ New or worsening mitral regurgitation or new VSD
❑ Sustained VT or VF

❑ Prior PCI within past 6 months or CABG
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
YES
 
 
 
NO
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Does the patient have negative ECG findings AND negative biomarkers?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Repeat ECG and biomarkers within next 6 hours and 12 hours
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ECG and biomarkers are both negative
 
At least one (ECG or biomarkers) is positive
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Calculate the risk of future adverse clinical outcomes:

Thrombolysis in Myocardial Infarction (TIMI) risk score, OR

GRACE score
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proceed to angiography
 
Intermediate or high risk
Initial invasive strategy
 
Low risk
Initial conservative strategy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Administer ONE of the following antiplatelet agents (before or at the time of PCI):
❑ Loading dose of P2Y12 receptor inhibitors

Clopidogrel 600 mg
Ticagrelor 180 mg
Prasugrel 60 mg

Prasugrel is contraindicated in case of prior history of strokes or TIAs, active pathological bleeding, age ≥75 years, when urgent coronary artery bypass graft surgery (CABG) is likely, body weight <60 kg, propensity to bleed, concomitant use of medications that increase the risk of bleeding
❑ IV GP IIb/IIIa inhibitors

Abciximab
❑ Loading dose 0.25 mg/kg IV bolus
❑ Maintenance dose 0.125 mg/kg/min
Eptifibatide
❑ Loading dose 180 mcg/kg IV bolus
❑ Another 180 mcg/kg IV bolus after 10 minutes
❑ Maintenance dose 2 mcg/kg/min
❑ Decrease infusion by 50% if creatinine clearance <50 mL/min
❑ Avoid in hemodialysis patients
Tirofiban
❑ Loading dose 25 mcg/kg
❑ Maintenance dose 0.15 mcg/kg/min
❑ Decrease infusion by 50% if creatinine clearance <30 mL/min

Administer ONE of the following anticoagulant therapy:
Unfractionated heparin

If GP IIb/IIIa receptor antagonist is planned
❑ 50- to 70-U/kg IV bolus
If no GP IIb/IIIa receptor antagonist is planned
❑ 70- to 100-U/kg bolus

Bivalirudin

❑ 0.75-mg/kg IV bolus, then 1.75–mg/kg/h infusion
❑ Additional bolus of 0.3 mg/kg if needed
❑ Decrease infusion to 1 mg/kg/h when creatinine clearance <30 mL/min
 
Administer ONE of the following antiplatelet agents (before OR at the time of PCI)

Before PCI
❑ Loading dose of P2Y12 receptor inhibitors

Clopidogrel (600 mg) (I-B), OR
Ticagrelor (180 mg) (I-B)

OR
❑ IV GP IIb/IIIa inhibitors (I-A)

Eptifibatide
❑ Loading dose 180 mcg/kg IV bolus followed by another bolus after 10 minutes
❑ Maintenance dose 2 mcg/kg/min, OR
Tirofiban
❑ Loading dose 25 mcg/kg
❑ Maintenance dose 0.15 mcg/kg/min


OR

At the time of PCI
❑ Loading dose of P2Y12 receptor inhibitors

Clopidogrel (600 mg) (I-A), OR
Ticagrelor (180 mg) (I-B), OR
❑ Prasugrel (60 mg) (I-B)

OR
❑ IV GP IIb/IIIa inhibitors (I-A)

Eptifibatide
❑ Loading dose 180 mcg/kg IV bolus followed by another bolus after 10 minutes
❑ Maintenance dose 2 mcg/kg/min, OR
Tirofiban
❑ Loading dose 25 mcg/kg
❑ Maintenance dose 0.15 mcg/kg/min
 
Administer ONE of the following antiplatelet agents:

Clopidogrel (I-B)

❑ Loading dose (300 mg)
❑ Maintenance dose for up to 12 months (75 mg)

Ticagrelor (I-B)

❑ Loading dose (180 mg)
❑ Maintenance dose for up to 12 months (90 mg twice daily)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consider urgent CABG if the coronary anatomy is not amenable to PCI and one of the following:[2]
❑ Patients with left main or left main equivalent disease
❑ Patients with three or two vessel disease involving the left anterior descending artery with left ventricular dysfunction
❑ Diabetic patients
 
❑ Perform an angiography
 
Does the patient experience any of the following?

❑ Recurrence of symptoms
Heart failure
❑ Serious arrhythmia

❑ Subsequent ischemia
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Perform an angiography

Administer upstream antiplatelet agent:
P2Y12 receptor inhibitors

Clopidogrel
❑ Loading dose (600 mg)
❑ Maintenance dose (75 mg), or
Ticagrelor
❑ Loading dose (180 mg)
❑ Maintenance dose (90 mg twice daily), or

❑ IV GP IIb/IIIa inhibitors

Eptifibatide
❑ Loading dose 180 mcg/kg IV bolus followed by another bolus after 10 minutes
❑ Maintenance dose 2 mcg/kg/min, or
Tirofiban
❑ Loading dose 25 mcg/kg
❑ Maintenance dose 0.15 mcg/kg/min
 
❑ Perform a stress test
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low risk on stress test
 
High risk on stress test
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Perform an angiography
 
 
 
 
 
 
❑ Continue aspirin for life
❑ Continue P2Y12 receptor inhibitors up to 12 months
Clopidogrel (75 mg once a day), or
Ticagrelor (90 mg twice a day)

❑ Discontinue GP IIb/IIIa inhibitors
❑ Continue antithrombotic therapy:

UFH for 48 hours, or
Enoxaparin for up to 8 days, or
Fondaparinux for up to 8 days
 
 
 
 
  1. Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE; et al. (2012). "2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". J Am Coll Cardiol. 60 (7): 645–81. doi:10.1016/j.jacc.2012.06.004. PMID 22809746.
  2. "ACC/AHA 2004 guideline update for coronary arter... [Circulation. 2004] - PubMed - NCBI".